

Home ▶ All Journals ▶ Medicine ▶ Expert Opinion on Therapeutic Patents ▶ List of Issues ▶ Volume 25, Issue 12 ▶ Patent cliff mitigation strategies: givi

Expert Opinion on Therapeutic Patents > Volume 25, 2015 - Issue 12



9.510 12 Views CrossRef citations to date Altmetric

Listen


Editorial

Patent cliff mitigation strategies: giving new life to blockbusters


Ashish Kumar Kakkar, MD DM (Assistant Professor)


Pages 1353-1359 | Published online: 15 Sep 2015

66 Cite this article ▶ https://doi.org/10.1517/13543776.2015.1088833




















Abstra

With sev

innovato

competi

increasii

impleme

A vari Thes cuts and

new forr pharmad thin, pro growth a

We Care About Your Privacy

We and our 911 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting I Accept enables tracking technologies to support the purposes shown under we and our partners process data to provide. Selecting Reject All or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Show Purposes link on the bottom of the webpage . Your choices will have effect within our Website. For more details, refer to our Privacy Policy. Here

We and our partners process data to provide:

Use precise geolocation data. Actively scan device

I Accept piry cliff, Reject All s to generic v and Show Purpose and dispensable. loss exist. tegic price es, such as remain

ies to drive

Authorized generics chiral switching drug repositioning lifecycle management patent cliff

Rx to over-the-counter switching

1. Introduction

Patent and market exclusivities are the cornerstone intellectual property incentives granting proprietary rights in pharmaceutical and biologics innovation. Since 2010, the 'big pharma' industry has been plagued by one of the biggest waves of drug patent expirations in history, a phenomenon commonly referred to as the 'patent cliff'. Loosely defined, it is the period when a significant number of current blockbuster drugs face expiry of their patents paving way for generic competition and consequent plummeting sales and revenues. With patents on several bestseller drugs about to expire over the ensuing 7-year period from 2014 to 2020, an estimated 259 billion USD in worldwide drug sales is at risk and nearly 46% of this is expected to materialize [1]. The prime reason why this figure falls short of 64% erosion that occurred between 2007 and 2013 is the fact that several impending patent expiries are for biologics. Biologics being much larger molecules requiring complex manufacturing processes are much more

Develop
risky end
drug at 2
Staggeri
policies
to maxir
strat
research
current t

uming and scription [2]. containment al industry lost of entists and rlie the

X

xtend

2. Wha

difficult

Several measures may be taken under the umbrella of 'lifecycle management (LCM) strategies' for fending off generic competition and extension of market monopoly (Table 1). The choice of strategy depends upon several factors, including available product-specific opportunities, expected return on investments (ROI), analysis of competitive landscape and available time frames. One of the most effective options encompasses developing and patenting novel formulations of the existing products with advantages in terms of enhanced patient adherence through reduced dosing frequency, improved adverse effect profile or better therapeutic outcomes. Classic examples of this strategy in action include Glucophage XR (metformin), Procardia XL (nifedipine), Seroquel XR (quetiapine) and Invega Sustena (paliperidone). Several qualitative case studies have suggested efficacy of new formulation strategies in extending patent protection and offsetting generic competition [3-6]. Similar strategy has been adopted by manufacturers of two blockbuster drugs losing patent protection in 2015, Namenda (memantine) and Copaxone (glatiramer acetate), who have launched longer-acting versions of their flagship drugs and are encouraging current patients to switch to newer formulations in a bid to minimize the impact of 'generic' entry into the market.

Table 1. Strategies for extending commercial lifecycle of drugs going off-patent.



Downl

X

'Drug re
investme
however
the off-la
be effe
prote
depressi
subsequ
a racem
maintair
of Nexiu

retain its

sivity is,
t preclude
vas found to
n of market
for
hich were
bstitution of
vantage in
troduction
Zeneca

cemic

demonstrated significantly less interindividual variability in pharmacokinetics and consequently superior bioavailability and clinical efficacy [7]. Other prominent examples include citalopram–escitalopram switch and the more recent follow on launches like armodafinil for modafinil and dexlansoprazole for lansoprazole. Number of prescriptions for both esomeprazole as well as escitalopram, continued to outnumber those of generic versions of racemates for 9 and 7 years since their launch, respectively [8]. A comprehensive analysis of secondary patents published in FDA's Orange Book, a listing of patents pertinent to approved drugs based on information provided by the innovator, for new molecular entities approved between 1998 and 2005 revealed their considerable impact. Secondary patents prolonged patent life, with independent formulation patents adding an average of 6.5 years, independent method of use patents adding 7.4 years, while independent patents on minor structural/chemical modifications, including isomers added 6.3 years of additional nominal patent term [9].

Another commonly utilized approach is patenting combination formulations containing two or more drugs in a single dosage unit and marketing it as a new product. For patients, such fixed-dose combinations (FDCs) can simplify complex treatment regimens, improve compliance, minimize emergence of resistance, balance adverse effects and provide synergistic benefits. For drug developers, they represent lucrative lifecycle extension strategies for sustained revenue generation. Fli Lilly introduced a combina

combina o reduce field of cannibal Combivir anti-HIV (lamivuo **Epzicom** and lamivud d tenofovir) (emtricii Gilead's and product dollars in d in October annual s entivizes 2014, sh develop w drug substan vised

interpre

ation for a

NCE exclusivity if it contains a drug substance, no active moiety of which has been approved in any other application under section 505(b) [12]. The earliest beneficiaries of this new policy include a hepatitis C drug combination, Harvoni (ledipasvir plus sofosbuvir) and Akynzeo (netupitant plus palonosetron) approved for chemotherapyinduced nausea and vomiting [13].

Switching branded prescription (Rx) drugs to over-the-counter (OTC) status can be a potentially viable strategy to ward off generic competition, although its feasibility varies with the product safety profile and nature of patient population it caters to. The global market for OTC pharmaceuticals is expected to exceed 170 billion USD by 2018 representing a compound annual growth rate of 3.8% over 2013 - 2018 [14]. AstraZeneca dealt a double 'switching' blow to generic competitors through Prilosec-Nexium chiral switching coupled shortly thereafter with Rx to OTC switching of Prilosec. History repeated itself in 2014 when Nexium nearing its patent expiration, gained FDA approval for OTC sales. Strategic drug pricing and entry into generic market via launch of 'authorized generic' or their own generic versions of the innovator drug are other defensive strategies that can make the market unattractive for potential generic competitors and help preserve monopoly profits. A 2014 study examined the experience of 18 pharmaceutical and biotech companies and the relative effectiveness of >20 LCM strategies for maximizing the commercial life of mature brands. The study rated strategic pricing as the most cost- and time-efficient approach. Also, with respect to time egy in

'Pay for

generati

agreeme competi

drug's p

Tradefierce

both bra

way to a

deals as

each year

legislation

Article contents



Related research

nts are paying the

ovator

US Federal

has been

rts. While

n effective

sider these

\$3.5 billion

. .

need of

nts have

3. Expert opinion

Several blockbuster pharmaceuticals are 'at risk' of losing as much as 90% of their sales revenues to generic competition as the steady flow of 'patent cliff' expiries continues. The best selling drugs set to lose patent protection in 2015 include Lantus, Abilify, Copaxone, Neulasta, Tracleer and Namenda. In addition to loss of exclusivity, the innovators are increasingly buffeted by decreased R&D efficiency even in the face of escalating costs of drug development, stricter regulatory procedures for drug approval and governmental measures to control healthcare costs via pro generic and price control policies. The current market scenario makes it imperative for pharmaceutical companies to focus on comprehensive lifecycle management planning to make the most of each branded product at every stage of its life. This should ideally begin early in the lifecycle of product, possibly in the pre-launch period. Such early planning and monitoring of progress can facilitate evaluation of a product's economic potential and aid in planning and successful implementation of other LCM strategies. A multitude of strategies, often used in combination, are available to mitigate the impending revenue loss when the innovator patent expires. Launch of new formulations and identifying newer indications and drug repositioning, are among the most effective

and prefimplemenovel FE that must approace expiry mapproace Reduration retaining complex drugs, a sustaine patent c

rs for drugs, pportunities at patent nough this e product. In or ovators in exceedingly blockbuster aial for yond the

Declaration of interest

The author has no relevant affiliation or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Bibliography

1. EvaluatePharma World Preview 2014, Outlook to 2020 [Internet]. 2014. Available from: http://www.evaluategroup.com/public/reports/EvaluatePharma-World-Preview-2014.aspx [Last accessed 15 April 2015]

Google Scholar

2. Tufts Center for the Study of Drug Development. Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs [Internet]. 2014. Available from: http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast [Last]

acces

Googl

3. Daido cycle

2014;



4. Manso ts. Pharm

Law Ir

Googl

5. Ellery ost of each

X

6. Dubey R, Dubey J. Pharmaceutical product differentiation: a strategy for strengthening product pipeline and life cycle management. J Med Mark Device Diagn Pharm Mark 2009;9(2):104-18

Google Scholar

7. Lindberg P, Keeling D, Fryklund J, et al. Review article: Esomeprazole-enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion. Aliment Pharmacol Ther 2003;17(4):481-8

PubMed Web of Science ® Google Scholar

8. Gellad WF, Choi P, Mizah M, et al. Assessing the chiral switch: approval and use of single-enantiomer drugs, 2001 to 2011. Am J Manag Care 2014;20(3):e90-7

PubMed | Web of Science ® | Google Scholar

9. Kapczynski A, Park C, Sampat B. Polymorphs and prodrugs and salts (Oh My!): an empirical analysis of "secondary" pharmaceutical patents. PLoS One 2012;7(12):e49470

0. Gileac. Interr scienc 20 Ap

Go

.1. Epzicc https:, [Last a Google ults 15/2/gilead-

ast accessed

X

icom.kivexa

.2. Guidance for industry: new chemical entity exclusivity determinations for certain fixed - combination drug products [Internet]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guida nces/ucm386685.pdf [Last accessed 22 April 2015] Google Scholar

.3. Gaffney A. FDA changes policy hours before approvals, giving companies gift potentially worth billions [Internet]. Available from: http://www.raps.org/Regulatory-Focus/News/2014/10/13/20549/FDA-Changes-Policy-Hours-Before-Approvals-Giving-Companies-Gift-Potentially-Worth-Billions/ [Last accessed 30 April 2015] Google Scholar

.4. OTC Pharmaceuticals. Global industry guide [Internet]. Available from: http://www.datamonitor.com/store/Product/otc pharmaceuticals global industry guid e?productid=ML00016-322 [Last accessed 30 April 2015]

.5. Lifecycle management excellence: high-performing strategies used to maximize

Google Scholar


gener

https:

potential of mature brands [Internet]. Available from: http://www.best-inclass.d 19F3? X opend Googl eral trade .6. Pay-Fo comm m: https onsumers-Googl s with .7. FTC St

y-2013-

Cited by 12



Information for

Authors

R&D professionals

Editors

Librarians

Societies

Opportunities

Reprints and e-prints

Advertising solutions

Accelerated publication

Corporate access solutions

Open access

Overview

Open journals

Open Select

Dove Medical Press

F1000Research

Help and information

Newsroom

Books

Keep up to date

Register to receive personalised research and resources by email

















X

or & Francis Group

